The latest price target for Vor Biopharma (NASDAQ:VOR) was reported by HC Wainwright & Co. on December 10, 2024. The analyst firm set a price target for $17.50 expecting VOR to rise to within 12 months (a possible 1810.27% upside). 17 analyst firms have reported ratings in the last year.

The latest analyst rating for Vor Biopharma (NASDAQ:VOR) was provided by HC Wainwright & Co., and Vor Biopharma reiterated their buy rating.

There is no last upgrade for Vor Biopharma

There is no last downgrade for Vor Biopharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vor Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vor Biopharma was filed on December 10, 2024 so you should expect the next rating to be made available sometime around December 10, 2025.

While ratings are subjective and will change, the latest Vor Biopharma (VOR) rating was a reiterated with a price target of $17.50 to $17.50. The current price Vor Biopharma (VOR) is trading at is $0.92, which is out of the analyst’s predicted range.